

Drug Class	Platform	Product Candidate	Indication (Targets)	Preclinical	Phase 1	Phase 2	Phase 3
------------	----------	-------------------	----------------------	-------------	---------	---------	---------

Oncology

mRNA	FixVac (fixed combination of shared cancer antigens)	BNT111	Advanced Melanoma (Adjuvant & Metastatic)				
		BNT112	Prostate Cancer				
		BNT113	HPV+ Head and Neck Cancer <sup>1</sup>				
		BNT114	Triple Negative Breast Cancer				
		BNT115, BNT116	Other Cancers, including Ovarian Cancer				
	iNeST (patient specific cancer antigen therapy)	RO7198457 (BNT122)	1L Melanoma with CPI <sup>2</sup>				
			Multiple Solid Tumors				
	Intratumoral Immunotherapy	SAR441000 (BNT131)	Solid Tumors ( <i>IL-12sc, IL-15sushi, GM-CSF, IFNα</i> )				
	RiboMabs (mRNA-encoded antibodies)	BNT141	Multiple Solid Tumors				
		BNT142	Multiple Solid Tumors ( <i>CD3+CLDN6</i> )				
	RiboCytokines (mRNA-encoded cytokines)	BNT151	Multiple Solid Tumors ( <i>Optimized IL-2</i> )				
		BNT152	Multiple Solid Tumors ( <i>IL-7</i> )				
		BNT153	Multiple Solid Tumors ( <i>IL-2</i> )				

Engineered Cell Therapies	CAR-T Cells	BNT211	Multiple Solid Tumors ( <i>CLDN6</i> )				
		BNT212	Pancreatic, Other Cancers ( <i>CLDN18.2</i> )				
	TCRs	To be selected	Solid Tumors				
		To be selected	All Tumors				

Antibodies	Next-Gen CP <sup>3</sup> Immunomodulators	GEN1046 (BNT311)	Multiple Solid Tumors ( <i>PD-L1x4-1BB</i> )				
		GEN1042 (BNT312)	Multiple Solid Tumors ( <i>CD40x4-1BB</i> )				
	Targeted Cancer Antibodies	MVT-5873 (BNT321)	Pancreatic Cancer ( <i>sLea</i> )				

SMIM <sup>4</sup>	Toll-Like Receptor Binding	BNT411	Solid Tumors ( <i>TLR7</i> )				
-------------------	----------------------------	--------	------------------------------	--	--	--	--

Other

mRNA	Infectious Disease Immunotherapies	BNT161	Influenza				
			Up to 10 Indications				
	Rare Disease PRT <sup>5</sup>	To be selected	5 Rare Disease Indications				

<sup>1</sup> BNT113 is currently being studied in an investigator-initiated Phase 1 trial, <sup>2</sup> Checkpoint Inhibitor, <sup>3</sup> Checkpoint, <sup>4</sup> Small Molecule Immunomodulators, <sup>5</sup> Protein Replacement Therapy